Dr. Charlene Gamaldo

Dr. Christopher Earley's research and clinical interests are devoted to Sleep Medicine with a special interest in Restless Legs Syndrome. His current research is focused on understanding the pathophysiology of Restless Legs Syndrome and further elucidating the value of various treatments in this syndrome. Dr. Earley received his medical degree as well as a PhD in Pharmacology from the University College in Galway, Ireland. He completed a full residency in Internal Medicine at Baylor Medical College and then went to the University of Virginia in Charlottesville to complete his residency in Neurology. After then spending a year at the NIH as a fellow in the Neurobiology Unit, Dr. Earley joined the faculty at Johns Hopkins in 1991. 2008 Professor, Department of Neurology, Johns Hopkins 1994- Associate Director, Sleep Disorders Center, JHBMC Education and Training: 1973 - B.S. (General), Villanova University 1974 - B.A. (Psychology), Arizona State University 1978 - Ph.D. (Pharmacology), National University of Ireland 1983 - M.B., B.Ch. ( Medicine), National University of Ireland 1983-1984 Internship, University Hospital, Galway, Ireland 1984-1987 Resident in Internal Medicine, Baylor College of Medicine, Houston, TX 1987-1990 Resident in Neurology, University of Virginia, Charlottesville, VA 1990-1991 Senior Staff Fellow, Neurobiology Unit, NIH/NIA Professional Experience: 1991- Full-time Staff Neurologist, Johns Hopkins 1992-1999 Assistant Professor, Department of Neurology, Johns Hopkins 1993-2001 Director, Acute Stroke Service, 1994- Associate Director, Sleep Disorders Center 1994-1999 Co-Director, Neurosciences Critical Care Unit 1996-2000 Director, Neurovascular Ultrasound Lab 1999-2008 Associate Professor, Department of Neurology, Johns Hopkins. Dr. Earley is highly rated in 6 conditions, according to our data. His top areas of expertise are Restless Legs Syndrome, Periodic Limb Movement Disorder, Narcolepsy, Seizures, and Gastrostomy.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is highly rated in 27 conditions, according to our data. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Dr. Alexander Pantelyat cares for patients with movement disorders such as Parkinson's disease and related syndromes, essential tremor, dystonia, chorea and normal pressure hydrocephalus. He also provides botulinum toxin injections for movement disorders and is involved in deep brain stimulation programming and intraoperative neurophysiological monitoring.His research explores atypical parkinsonian disorders, such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders; and music-based rehabilitation of neurodegenerative diseases.Dr. Pantelyat earned his medical degree from Temple University School of Medicine in Philadelphia, where he was elected a member of the Alpha Omega Alpha Honor Medical Society and received the Matthew T. Moore Prize in Neurology. He completed his residency training in Neurology ​at the University of Pennsylvania in Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania/Philadelphia VA Medical Center. As part of his fellowship, Dr. Pantelyat also completed the Clinical Research Certificate Program at the Center for Clinical Epidemiology and Biostatistics. He is a 2013 American Academy of Neurology Palatucci Advocacy Leader and grant recipient. Dr. Pantelyat is highly rated in 39 conditions, according to our data. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Movement Disorders.